What is Acid Reflux

In late 2006, EndoGastric Solutions, the world leader in endoluminal intragastric surgery, completed enrollment in a pivotal trial for the Endoluminal Fundoplication (ELF) procedure treating 84 patients – without incision – using the EsophyX device at seven leading European Medical Centers for purposes of obtaining U.S. FDA clearance. [click link for full article]

New, updated guidelines for esophageal reflux testing appear in The American Journal of Gastroenterology. Developed and approved by the American College of Gastroenterology, these guidelines summarize advances in gastroesophageal reflux disease (GERD) diagnostic testing and how they have modified the clinical management of esophageal disorders. [click link for full article]

A new study, published in the journal “Digestion”, determined the diagnostic and therapeutic response of the Reflux Disease Questionnaire (RDQ) using the symptom association probability as reference. The symptom association probability objectively determines with a Fisher exact test whether symptoms are due to reflux events taking all symptom episodes and reflux events into account. In addition, the RDQ’s construct validity and its relationship to quality of life were ascertained. [click link for full article]

Celecoxib, a nonsteroidal anti-inflammatory drug (NSAID), did not prevent cancer in patients with Barrett’s esophagus in a placebo-controlled study.The incidence of Barrett’s esophagus – a precancerous change in the lining of the esophagus that increases the risk of developing esophageal cancer – is on the rise in the United States. Previous studies have suggested that aspirin and other NSAIDs might decrease the risk of esophageal cancer. [click link for full article]

Cerimon Pharmaceuticals, Inc., announced today it has begun enrolling patients in a Phase 2b clinical study, for its lead product candidate basiliximab (Simulect(R)), titled ARREST UC-1 (Achieve Remission & Reduce or Eliminate Steroid Therapy in Ulcerative Colitis) for the treatment of ulcerative colitis, a common type of Inflammatory Bowel Disease (IBD). [click link for full article]

EndoGastric Solutions, the world leader in endoluminal intragastric surgery, is pleased to announce that it has received clearance from the US FDA for its StomaphyX device. StomaphyX is indicated for use in endoluminal transoral tissue approximation and ligation in the GI tract. “This is a major event in the history of our company,” said Thierry Thaure, EndoGastric Solutions’ President and Chief Executive Officer. [click link for full article]